`
`Slayback Pharma announces the final approval and launch of Generic Zovirax (Acyclovir) Ointment 5%
`
`Slayback Pharma announces the nal
`approval and launch of Generic Zovirax
`(Acyclovir) Ointment 5%
`
`USA - English
`
`NEWS PROVIDED BY
`Slayback Pharma LLC
`
`24 Dec, 2016, 00:26 GMT
`
`PRINCETON JUNCTION, New Jersey, Dec. 24, 2016 /PRNewswire/ -- Slayback Pharma LLC is
`pleased to announce the launch of Generic Zovirax Ointment (Acyclovir Ointment) 5%, by its
`out-licensee - Sandoz (Fougera). Slayback had developed the product and out-licensed the
`sales and marketing rights to Sandoz. The ANDA led by Sandoz (Fougera) was approved on
`May 11, 2016.
`
`The product is a generic version of Valeant's Zovirax Ointment (Acyclovir Ointment), which is
`indicated in the management of initial genital herpes and in limited non-life-threatening
`mucocutaneous Herpes simplex virus infections in immunocompromised patients. Acyclovir
`Ointment is contraindicated in patients who develop hypersensitivity to the components of the
`formulation. Acyclovir Ointment is intended for cutaneous use only and should not be used in
`the eye.
`
`As per the agreement between Sandoz and Slayback, terms of which remain con dential,
`Sandoz will continue to pay Slayback a share of the pro ts generated from the sale of Acyclovir
`Ointment in the USA.
`
`https://www.prnewswire.com/in/news-releases/slayback-pharma-announces-the-final-approval-and-launch-of-generic-zovirax-acyclovir-ointment-5-608… 1/2
`
`
`
`Eye Therapies Exhibit 2127, 1 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`
`
`8/16/22, 5:08 PM
`Slayback Pharma announces the final approval and launch of Generic Zovirax (Acyclovir) Ointment 5%
`"Slayback's core focus is the development of complex generics primarily in parenteral and other
`non-solid pharmaceutical products by connecting the dots across various technologies,
`science, regulatory and intellectual property traditions. The successful development and
`approval of a complex generic formulation of Acyclovir Ointment meeting FDA's standards is a
`testimony to this effort," said Ajay K Singh, Chief Executive Of cer of Slayback Pharma LLC.
`
`About Slayback Pharma LLC
`
`Slayback Pharma LLC is a specialty pharmaceutical company focused on developing,
`manufacturing and sourcing of complex generic pharmaceutical products, with a speci c
`emphasis on complex injectables and other non-solid oral products. Slayback has created a
`unique portfolio of complex generic by smart product selection and execution and connecting
`various dots through a network of contract R&D laboratories and manufacturing organizations,
`comprising smart and rapid development capabilities, sophisticated manufacturing and
`innovative drug delivery technologies.
`
`SOURCE Slayback Pharma LLC
`
`https://www.prnewswire.com/in/news-releases/slayback-pharma-announces-the-final-approval-and-launch-of-generic-zovirax-acyclovir-ointment-5-608… 2/2
`
`
`
`Eye Therapies Exhibit 2127, 2 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
